Clonidine Dosing for Pediatric Patients
For ADHD in children, start with 0.1 mg orally at bedtime and titrate by 0.1 mg/day weekly up to 0.2-0.4 mg/day divided into 2-4 doses, with a maximum of 0.4 mg/day. For sedation and analgesia in critically ill children, oral clonidine 2-5 mcg/kg/day divided every 6-8 hours is effective, while transdermal patches deliver 2.3-20 mcg/kg/day 1, 2.
Oral Clonidine Dosing
ADHD Treatment
- Initial dose: 0.1 mg at bedtime (reduces transient side effects like dry mouth and drowsiness) 3
- Titration: Increase by 0.1 mg/day at weekly intervals based on response 3
- Maintenance: 0.2-0.4 mg/day divided into 2-4 doses 1
- Maximum: 0.4 mg/day for most pediatric patients 3
The FDA-approved adult dosing starts at 0.1 mg twice daily, but pediatric ADHD management benefits from evening-weighted dosing to minimize daytime sedation 3.
Sedation and Analgesia in Critical Care
- Dosage range: 2-15 mcg/kg/day divided every 6-8 hours 2
- Common starting dose: 2-5 mcg/kg/day 2
- High-dose range: Up to 9 mcg/kg/hour has been used safely in severe dystonia cases 4
Important pharmacokinetic consideration: Oral bioavailability in children is only 55.4%, significantly lower than the 75-100% seen in adults 5. This means children require higher per-kilogram doses than adults to achieve equivalent plasma concentrations.
Neonatal Abstinence Syndrome
- Recommended dose: 1.5 mcg/kg every 4 hours starting in the second week of life 6
- Age-dependent clearance: Clonidine clearance matures rapidly during the first month of life, requiring dose adjustments based on postnatal age 6
- Weight-based adjustment: CL/F = 15.2 × [body weight (kg)/70]^0.75 × [PNA (day)^0.441/(4.06^0.441 + PNA (day)^0.441)] 6
Transdermal Clonidine Dosing
Available Patch Sizes
Pediatric Application
- Dosage range: 2.3-20 mcg/kg/day 2
- Application: Change patch weekly, rotating sites 7
- Onset: Therapeutic levels achieved 2-3 days after initial application 7
- Offset: Plasma levels persist 8 hours after removal, then decline over several days 7
Critical safety warning: Never cut transdermal patches. Cut patches produce variable and significantly higher serum concentrations than whole patches, increasing risk of toxicity 2. Only use whole, intact patches.
Route-Specific Considerations
Oral Administration
- Advantages: Flexible dosing, rapid titration possible
- Disadvantages: Lower bioavailability (55.4%) requires higher doses 5
- Absorption: Variable and relatively slow (Tmax 1.04 hours, Cmax 0.77 mcg/L with 4 mcg/kg dose) 5
- Food effects: Can be given with apple juice or fruit drinks 5
Transdermal Administration
- Advantages: Steady-state delivery, improved adherence, "around-the-clock" effects 1
- Disadvantages: 2-3 day onset delay, slower dose adjustments 7
- Duration: 7-day continuous delivery 7
Intravenous Infusion (Critical Care)
- Dosage range: 0.1-9 mcg/kg/hour 4
- Typical range: 2-20 mcg/kg/min 8
- Advantages: Precise titration, rapid onset
- Use: Reserved for severe acute exacerbations requiring intensive monitoring 4
Age-Specific Dosing Recommendations
Neonates (0-28 days)
- Week 1: Use with extreme caution; limited safety data 6
- Week 2+: 1.5 mcg/kg every 4 hours orally 6
- Adjustment: Increase dose as clearance matures with postnatal age 6
Infants and Young Children (1 month-5 years)
- ADHD: Start 0.05-0.1 mg at bedtime, titrate slowly 9
- Sedation: 2-5 mcg/kg/day divided every 6-8 hours 2
School-Age Children (6-12 years)
- ADHD: 0.1 mg at bedtime initially, titrate to 0.2-0.4 mg/day divided 3
- Optimal dose (simulation): 30 mcg/kg/day orally for maximal α-2 adrenergic activity 9
Adolescents (13-17 years)
- ADHD: 0.9 mg/day orally (can approach adult dosing) 9
- Maximum: 0.4 mg/day unless under specialist supervision 3
Monitoring and Safety
Cardiovascular Monitoring
- Blood pressure: Monitor for hypotension (common adverse effect) 1, 2
- Heart rate: Monitor for bradycardia 1, 2
- Frequency: More intensive monitoring during titration and with high doses 4
Common Adverse Effects
- Somnolence/sedation: Most frequent, administer larger doses at bedtime 1, 3
- Fatigue and irritability 1
- Dry mouth and drowsiness: Minimize with evening dosing 3
- Hypotension and bradycardia: Dose-dependent 1, 2
Critical Safety Considerations
- Rebound hypertension: Taper gradually when discontinuing; do not stop abruptly 3
- Overdose risk: As little as 0.1 mg can cause toxicity in children 7
- Patch ingestion: Accidental ingestion reported in children; store securely 7
- Respiratory depression: Less than benzodiazepines but still possible at high doses 4
Tapering Protocol
When discontinuing clonidine:
- Reduce dose gradually over 2-4 days minimum to avoid rebound hypertension 3
- Monitor blood pressure during taper and for several days after discontinuation 7
- Plasma levels persist for 8 hours after patch removal, then decline slowly over days 7
Special Populations
Renal Impairment
- Lower initial doses recommended 3
- Careful monitoring required 3
- Hemodialysis: No supplemental dose needed (minimal removal) 3
Hepatic Impairment
- No specific pediatric dosing adjustments established; use caution
Clinical Pearls
The 2024 PBPK modeling study provides the most rigorous dosing recommendations: 30 mcg/kg/day orally for neonates and 0.9 mg/day for children 6-17 years to achieve target concentrations for maximal α-2 adrenergic activity 9. These doses account for the lower oral bioavailability in children compared to adults.
For critically ill children requiring sedation: Oral clonidine 2-5 mcg/kg/day divided every 6-8 hours reduces benzodiazepine and opioid requirements without significant cardiorespiratory depression, even at doses up to 9 mcg/kg/hour 2, 4.
Transdermal patches offer convenience but require 2-3 days to reach therapeutic levels, making them unsuitable for acute management 7. They work best for chronic conditions like ADHD where steady-state delivery is advantageous 1.